Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.55 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.36 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2123539 | 1.00 | GRM2 (0.55) | GRM2SCN5AMCHR2MCHR1TLR7 | |
| SCHEMBL8120477 | 0.85 | GRM2 (0.55) | GRM2SCN5ATRPA1ALDH1A1PLAT | |
| SCHEMBL3090130 | 0.84 | GRM2 (0.62) | GRM2SCN5ATRPA1ALDH1A1PLAT | |
| SCHEMBL2122976 | 0.82 | GRM2 (0.76) | GRM2SCN5ANPC1ALDH1A1RAB9A | |
| SCHEMBL13180434 | 0.81 | GRM2 (0.63) | GRM2SCN5ATRPA1ALDH1A1PLAT | |
| SCHEMBL3085170 | 0.77 | L3MBTL1 (0.36) | NPC1RAB9A | |
| SCHEMBL2121482 | 0.77 | GRM2 (0.53) | GRM2TLR7NPC1ALDH1A1RAB9A | |
| SCHEMBL30789128 | 0.77 | GRM2 (0.53) | GRM2TLR7NPC1ALDH1A1RAB9A | |
| SCHEMBL13123578 | 0.77 | GRM2 (0.53) | GRM2TLR7NPC1ALDH1A1RAB9A | |
| SCHEMBL3097255 | 0.76 | GRM2 (0.51) | GRM2SCN5AALDH1A1PLATSCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280082-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators | ASTRAZENECA AB (SE) | 2010-11-04 | — | — | US | disclosed |
| US-7799792-B2 | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators 841 | ASTRAZENECA AB (SE) | 2010-09-21 | — | — | US | disclosed |
| US-7799792-B2 | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators 841 | ASTRAZENECA AB (SE) | 2010-09-21 | — | — | US | disclosed |
| US-20080306088-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-20080306088-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841 | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280082-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators | GRM1, GRM3, GRM2 | GRM2 3/4885SCN5A 1294/4885MCHR2 337/4885 |
| US-20080306088-A1 | Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators 841 | GRM1, GRIN1, GRM3 | GRM2 5/4885SCN5A 1180/4885MCHR2 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.